Kongenitale amegakaryozytäre Thrombozytopenie (CAMT) - ein Defekt des Thrombopoetin-Rezeptors c-Mpl

Zusammenfassung.

Bei der angeborenen amegakaryozytären Thrombozytopenie (CAMT) handelt es sich um ein seltenes „bone marrow failure”-Syndrom, bei dem eine zunächst isoliert auftretende Thrombozytopenie mit hypomegakaryozytärem Knochenmark im Laufe der ersten Lebensjahre in eine Panzytopenie übergeht. Die Knochenmarktransplantation stellt der-zeit die einzige kurative Behandlungsmethode dar. Thrombopoetin (TPO) ist der wichtigste Wachstumsfaktor für die Regulation der Megakaryozytopoese und Thrombozytopoese. Wir führten Laboruntersuchungen an Blutplasma, hämatopoetischen Vorlauferzellen und Thrombozyten von CAMT-Patienten durch, um die TPO-Produktion und die Reaktivität der verschiedenen Zellen auf diesen Botenstoff zu testen. Obwohl wir im Plasma von CAMT-Patienten, wie auch bei anderen hypomegakaryozytären Thrombozytopenien, hohe TPO-Serumspiegel nachweisen konnten, zeigten die untersuchten Zellen keine Reaktivität auf TPO: Weder die hämatopoetischen Vorläuferzellen im Knochenmark noch die Thrombozyten ließen sich durch TPO in vitro stimulieren. Mit Hilfe durchflusszytometrischer Untersuchungen konnten wir diese fehlende TPO-Reaktivität von Thrombozyten bei CAMT-Patienten auf die defekte Expression des TPO-Rezeptors c-Mpl auf der Oberfläche der Thrombozyten zurückführen. Ursache hierfür sind Mutationen im c-mpl-Gen, die entweder zu einem kompletten Ausfall oder zu einer strukturellen Veränderung des c-Mpl-Proteins mit Funktionseinschränkung führen. TPO spielt nicht nur in der Megakaryozytopoese, sondern auch in der Regulation früher, multipotenter hämatopoetischer Zellen eine wichtige Rolle. Der Defekt im TPO-Rezeptor c-Mpl bei CAMT scheint demzufolge auch für die Ausweitung des hämatopoetischen Defekts auf die anderen Zellreihen und die Entwicklung der Panzytopenie verantwortlich zu sein.

Congenital amegakaryocytic thrombocytopenia (CAMT) is a very rare bone marrow failure syndrome presenting with isolated hypomegakaryocytic thrombocytopenia at birth developing into a pancytopenia during the first years of life. Bone marrow transplantation is the only curative therapy for this disease so far. Thrombopoietin (TPO) is the most important hematopoietic growth factor for the regulation of megakaryopoiesis and thrombopoiesis. We investigated TPO production and reactivity in CAMT patients. TPO plasma levels were high like in other forms of thrombocytopenia due to ineffective megakaryopoiesis. However, we found a defective reactivity to TPO: Neither hematopoietic progenitor cells in the bone marrow nor platelets from the peripheral blood did respond to TPO. Flow cytometric investigations demonstrated a lack of expression of the TPO receptor c-Mpl on the surface of platelets. Accordingly, we found mutations in the c-mpl gene, which are predicted to lead to a complete or at least partial loss of function of the TPO receptor. TPO is not only involved in the regulation of megakaryocytopoiesis but also in early hematopoiesis. This seems to be the reason for the general defect in hematopoiesis in CAMT leading to the development of pancytopenia.

Kongenitale amegakaryozytäre Thrombozytopenie - TPO - c-Mpl - Hämatopoese - Panzytopenie

Congenital amegakaryocytic thrombocytopenia - TPO - c-Mpl - hematopoiesis - pancytopenia

Literatur

• 01 Alexander  W S et al. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietin receptor c-Mpl.  Blood. 1996;;  87 2162-2170
• 02 Alter  B P, Young  N S. The bone marrow failure syndromes. In: Nathan DG, Orkin SH (Hrsg). Nathan and Oski's Hematology of Infancy and Childhood. WB Saunders Company, Philadelphia; 1998:
• 03 Ballmaier  M et al. Thrombopoietin in patients with congenital thrombocytopenia and absent radii: elevated serum levels, normal receptor expression, but defective reactivity to thrombopoietin.  Blood. 1997;;  90 612-619
• 04 Ballmaier  M et al. Defective TPO-reactivity in congenital amegakaryocytic thrombocytopenia [abstract].  Blood. 1999;;  94 44a
• 05 Ballmaier  M et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia.  Blood. 2001;;  97 139-146
• 06 Ballmaier  M et al. Response: Screening for c-mpl mutations in patients with congenital amegakaryocytic thrombocytopenia identifies a polymorphism.  Blood. 2001;;  97 3676
• 07 Bartley  T D et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl.  Cell. 1994;;  77 1117-1124
• 08 Borge  O J et al. Ability of early acting cytokines to directly promote survival and suppress apoptosis of human primitive CD34 ⁺ CD38 ^- bone marrow cells with multilineage potential at the single-cell level: Key role of thrombopoietin.  Blood. 1997;;  90 2282-1192
• 09 Carver-Moore  K et al. Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice.  Blood. 1996;;  88 803-808
• 10 Choi  E S et al. The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis.  Br J Haematol. 1996;;  95 227-233
• 11 Cohen-Solal  K et al. Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis.  Blood. 1996;;  88 2578-2584
• 12 Cremer  M et al. Serum levels of thrombopoietin, IL-11, and IL-6 in pediatric thrombocytopenias.  Ann Hematol. 1999;;  78 401-407
• 13 de Sauvage  F J et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c- Mpl ligand.  Nature. 1994;;  369 533-538
• 14 Eilers  M et al. Thrombopoietin Acts Synergistically on Ca(2+) Mobilization in Platelets Caused by ADP or Thrombin Receptor Agonist Peptide.  Biochem Biophys Res Comm. 1999;;  263 230-238
• 15 Freedman  M H, Estrov  Z. Congenital amegakaryocytic thrombocytopenia: an intrinsic hematopoietic stem cell defect.  Am J Pediatr Hematol Oncol. 1990;;  12 225-230
• 16 Freedman  M H, Doyle  J J. Inherited bone marrow failure syndromes. In: Lilleyman JS et al. (Hrsg). Pediatric Hematology. Churchill Livinstone, London; 1999:
• 17 Horikawa  Y et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia.  Blood. 1997;;  90 4031-4038
• 18 Ichikawa  N et al. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenic purpura.  Thromb Haemost. 1996;;  76 156-160
• 19 Ihara  K et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia.  Proc Natl Acad Sci USA. 1999;;  96 3132-3136
• 20 Kato  T et al. Purification and characterization of thrombopoietin.  J Biochem. 1995;;  118 229-236
• 21 Kaushansky  K. Thrombopoietin: The primary regulator of platelet production.  Blood. 1995;;  86 419-431
• 22 Kimura  S et al. Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin.  Proc Natl Acad Sci USA. 1998;;  95 1195-1200
• 23 Kobayashi  M et al. Thrombopoietin supports proliferaton of human primitive hematopoietic cells in synergy with stell factor and/or interleukin-3.  Blood. 1996;;  88 429-436
• 24 Ku  H et al. Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice.  Blood. 1996;;  87 4544-4551
• 25 Kuter  D J et al. The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production.  Proc Natl Acad Sci USA. 1994;;  91 11104-11108
• 26 Kuter  D J, Rosenberg  R D. The reciprocal relationship of thrombopoietin (c-mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit.  Blood. 1995;;  85 2720-2730
• 27 Lok  S et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo.  Nature. 1994;;  369 565-568
• 28 Methia  N et al. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis.  Blood. 1993;;  82 1395-1401
• 29 Mignotte  V et al. Structure and transcription of the human c-mpl gene (MPL).  Genomics. 1994;;  20 5-12
• 30 Moliterno  A R et al. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.  N Engl J Med. 1998;;  338 572-580
• 31 Mukai  H Y et al. Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura.  Thromb Haemost. 1996;;  76 675-678
• 32 Nagata  Y et al. Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis.  Thromb Haemost. 1997;;  77 808-814
• 33 Nichols  K E et al. Familial dyserythropoietic anaemia and thrombocytotopenia dua to an in inherited mutation in GATA1.  Nat Gen. 2000;;  24 266-270
• 34 O'Gorman Hughes  D W. Aplastic anemia in childhood. III. Constitutional aplastic anaemia and related cytopenias.  Med J Austr. 1974;;  1 519
• 35 Sitnicka  E et al. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells.  Blood. 1996;;  87 4998-5005
• 36 Skoda  R C et al. Murine c-mpl: a member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal.  EMBO J. 1993;;  12 2645-2653
• 37 Solar  G P et al. Role of c-mpl in early hematopoiesis.  Blood. 1998;;  92 4-10
• 38 Souyri  M et al. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors.  Cell. 1990;;  63 1137-1147
• 39 Stoffel  R et al. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets.  Blood. 1996;;  87 567-573
• 40 van den Oudenrijn  S et al. Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia.  Br J Haematol. 2000;;  110 441-448
• 41 Vigon  I et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily.  Proc Natl Acad Sci USA. 1992;;  89 5640-5644
• 42 Vigon  I et al. Characterization of the murine Mpl proto-oncogene, a member of the hematopoietic cytokine receptor family: molecular cloning, chromosomal location and evidence for a function in cell growth.  Oncogene. 1993;;  8 2607-2615